Vandetanib
Back to searchMolecule Structure
Scientific Name
Vandetanib
Description of the Drug
Vandetanib is an antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05294
http://www.drugbank.ca/drugs/DB05294
Brand Name(s)
Caprelsa, Zactima
Company Owner(s)
Genzyme Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Ephrin receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2363043 |
Tyrosine-protein kinase BRK | SINGLE PROTEIN | INHIBITOR | CHEMBL4601 |
Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
Tyrosine-protein kinase receptor RET | SINGLE PROTEIN | INHIBITOR | CHEMBL2041 |
Tyrosine-protein kinase TIE-2 | SINGLE PROTEIN | INHIBITOR | CHEMBL4128 |
Tyrosine-protein kinase SRC | SINGLE PROTEIN | INHIBITOR | CHEMBL267 |
Epidermal growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2363049 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL9044 | |
PharmGKB | PA166118341 | |
DrugBank | DB05294 | |
PubChem: Thomson Pharma | 14761077 | |
PubChem | 3081361 | |
Mcule | MCULE-4705827953 | |
LINCS | LSM-1199 | |
Nikkaji | J1.720.281B | |
PDBe | ZD6 | |
BindingDB | 21 | |
EPA CompTox Dashboard | DTXSID1046681 | |
DrugCentral | 4178 | |
Brenda | 227978 | 127382 |
ChemicalBook | CB01011762 | |
Guide to Pharmacology | 5717 | |
rxnorm | CAPRELSA | VANDETANIB |
PubChem: Drugs of the Future | 12015522 | |
ChEBI | 49960 | |
ZINC | ZINC000053683345 |